Abivax S.A. (ABVX) stock
ABVXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as AAVXF
$90.20−1.24 (-1.36%)
Close on Nov 12, 2026Market cap $7.08BP/E –Yield –
Abivax cash
Cash and short-term investments held at the end of each period.
Abivax's cash was €387.99M at Jun 30, 2026. For fiscal 2025 it was €516.69M, up 258.3% from the year before. The highest annual figure on record is €516.69M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €516.69M | +258.3% |
| FY2024 | Dec 31, 2024 | €144.22M | -42.8% |
| FY2023 | Dec 31, 2023 | €251.94M | +834.8% |
| FY2022 | Dec 31, 2022 | €26.95M | -55.6% |
| FY2021 | Dec 31, 2021 | €60.70M | +107.2% |
| FY2020 | Dec 31, 2020 | €29.30M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | €387.99M | +536.6% |
| Q1 FY2026 | Mar 31, 2026 | €477.42M | +360.9% |
| Q4 FY2025 | Dec 31, 2025 | €516.69M | +258.3% |
| Q3 FY2025 | Sep 30, 2025 | €589.70M | +226.8% |
| Q2 FY2025 | Jun 30, 2025 | €60.95M | -72.6% |
| Q1 FY2025 | Mar 31, 2025 | €103.58M | -57.1% |
| Q4 FY2024 | Dec 31, 2024 | €144.22M | -42.8% |
| Q3 FY2024 | Sep 30, 2024 | €180.45M | +569.6% |
| Q2 FY2024 | Jun 30, 2024 | €222.32M | +266.2% |
| Q1 FY2024 | Mar 31, 2024 | €241.61M | +724.5% |
| Q4 FY2023 | Dec 31, 2023 | €251.94M | – |
| Q4 FY2022 | Dec 31, 2022 | €26.95M | – |
| Q4 FY2021 | Dec 31, 2021 | €60.70M | – |
| Q4 FY2020 | Dec 31, 2020 | €29.30M | – |
See a number that looks wrong?